Janice M. LeCocq, Ph.D.

Chairman of the Board & Chief Executive Officer.


Jan began her career in life sciences in 1980 at Montgomery Securities and was one of the first securities analysts on Wall Street to cover the emerging biotechnology industry. Subsequently, she moved into corporate finance as a General Partner at Montgomery during which time her clients included Amgen, Chiron, Genzyme, Mycogen, Gensia Pharmaceuticals and Total Pharmaceutical Care. While she was at Montgomery Securities the firm became a leading underwriter of public and private equity, raising over $400 million for emerging life sciences companies. Jan was recruited to ICOS Corporation in 1990, a company founded by her former client, Dr. George Rathmann, the founding CEO of Amgen, and she served as EVP, Finance and Administration and as a member of the Board of Directors for four years. She led the team that raised over $90 million in financing for ICOS. In 1994, Jan was recruited to become CEO of Gryphon Sciences, a biotech startup based on novel protein synthesis technology licensed from The Scripps Institute. There she raised $13 million and recruited the initial scientific and business teams. Since 1998, Jan has been consulting with and serving as a Board Member to a variety of life science companies. She holds a Ph.D. in Medical Anthropology from Stanford University.

Susan K. Clymer

EVP of Business Development


Susan is responsible for Corporate Strategy and Business Development at Parvus. Over the past 30 years, Susan has worked in the public, private, as well as the academic sectors. Susan began her career as an analyst with the U.S. Congressional Office of Technology Assessment (OTA) in Washington, D.C., where she co-authored two major biotechnology reports. She then moved to the private sector where she managed the business development activities of two public biotech firms, both of which were later acquired by major healthcare companies. Until her current role at Parvus, Susan managed an active business development consulting practice with a special focus on Japan. Her clients have included many leading U.S. bioventure and pharmaceutical companies, several U.S. venture funds, and Japanese pharmaceutical and industrial companies. Susan has been involved in the formation, management, and acquisition of both public and private U.S. and Japanese venture-backed biotech companies, and has served on the board of directors of several private and public companies. Susan also was a co-founder of Sapient Health Network, a web-based consumer health company acquired and rebranded as WebMD in 1999, and also WellnessFx. Susan was a Fulbright Scholar and a graduate of Georgetown University, School of Foreign Service.

Pere Santamaria M.D. Ph.D.

Chief Scientific Officer, Member of the Board of Directors.


Dr. Santamaria holds both an MD and PhD from University of Barcelona, Spain, and completed post-doctoral studies at the University of Minnesota prior to joining the Faculty of Medicine at the University of Calgary as Assistant Professor in 1992. He is an internationally recognized immunologist specialized in T1D and a Professor in the Department of Microbiology & Infectious Diseases, Chair of the Immunology Research Group at the Institute of Infection, Inflammation & Immunity, Julia McFarlane Chair in Diabetes Research, and Director of the Julia McFarlane Diabetes Research Centre, all in the Faculty of Medicine at the University of Calgary. Pere has received several honors and awards, including the Alberta Heritage Foundation for Medical Research Senior Scholar, Scientist and Senior Scientist awards, the Canadian Diabetes Association Young Investigator award and the Juvenile Diabetes Research Foundation Scholar award and most recently the winner of the 2013 ASTech Foundation’s Outstanding Leadership in Alberta Technology award. He has published over 150 publications, many in high-impact journals, and he is a regularly invited speaker at national and international forums. He sits on the editorial board of a number of journals and numerous national and international grant review panels.

Jord Cowan

VP of Operations.


Mr. Cowan holds Bachelor of Science (biochemistry & chemistry) from the University of Calgary with advanced studies in medical science research. After additional financial training Jord became involved with early-stage company development in 2005. Jord began his career as a founder of several for-profit and non-profit companies. Jord also worked as an associate with Argon Venture Partners, a cross-border early-stage venture capital firm and as an analyst for the Venture Alberta Forum (formerly Keiretsu Forum), which is an investment community of accredited private equity investors, venture capitalists and corporate/institutional investors. Prior to Parvus he was a manager of new company formation at University Technologies International LP (UTI), at the University of Calgary. Jord was instrumental in the early research and intellectual property activities that led to the formation of Parvus in 2009. Since then he has managed the R&D commercialization activities of Parvus, total expenditures in excess of $10 million dollars. As a result of his work with Parvus, Jord was recently an awardee of the Alberta Innovates - Commercialization Associate program.

Ken Porter

Member of the Board of Directors.


Mr. Porter is the Vice President of Intellectual Property Management at Innovate Calgary, the technology company business incubator and technology transfer agent for the University of Calgary, Alberta, Canada. Innovate Calgary is also an investor in Parvus. Ken brings over fifteen years of experience in technology commercialization. He became interested in intellectual property when he and a team of chemists at Duke University invented a DNA sequencing technology for the Human Genome Sequencing Project. He entered the technology transfer profession at Duke, and then moved to the University of Colorado to lead re-building the tech transfer office at CU-Boulder. From CU, he moved to San Antonio to build the first multi-institutional tech transfer office at the University of Texas. He has also provided consulting services to liberal arts institutions with the aim of creating networks that employ streamlined technology transfer operations supported by a common database and expert social networks.  Ken holds PhD (Chemistry) and MBA degrees from Duke University, and a B.S. degree (Zoology) from the University of North Carolina at Chapel Hill.

Stephen Zaruby

Member of the Board of Directors.


Mr. Zaruby has spent his career in the biopharmaceutical industry and he is currently the CEO of a publically-traded Canadian biotech company. Mr. Zaruby was President of Zymogenetics until it was acquired by Bristol-Myers Squibb in 2010 for $885 million. Before that, Mr. Zaruby served as Vice President, Global Head, Hospital/Surgical Business Unit of Bayer HealthCare Pharmaceuticals. Mr. Zaruby served as Director, Global Strategic Marketing of Bayer AG. Prior to that, Mr. Zaruby held various positions in sales, marketing and product development within the Bayer group of companies. Mr. Zaruby holds a B.Sc. from the University of Calgary. He has a long- standing association with the Calgary diabetic community and Stephen is also on the Board of Directors of the Juvenile Diabetes Research Foundation International, Seattle Guild.

Robert J. Zimmerman, S.D.


Bob has over 25 years experience in translational R&D in both public and privately held companies.  A track-record of successful IND filings, product approvals, and new indications support.  Independent consultant to the biopharmaceutical industry on pipeline evaluations, drug development strategies, non-clinical programs to support regulatory filings and clinical development, and R&D strategy.  Previous experience includes: 1) President, Chief Operating Officer, Executive VP Research and Development, Signature BioScience, Inc., 2) Vice President, Biotechnology Research, Bayer Corporation, 2) Head, International Oncology Team, 3) Senior Director, Director, Biopharmaceutical Evaluation, Chiron Corporation, 4) Director, Biological Therapeutics Development, Director, Department of Pharmacology, Scientist, Pharmacology Dept., Cetus Corporation.

Jerome Lewis, Ph.D.

CMC Consultant.


Jerry has over 35 years of experience in leading successful R&D teams as well as product development through commercial sales.  His previous experience includes senior management positions in R&D, product development, scale-up, and manufacturing of products during development and for commercial sales.  He has also managed the manufacturing and biological sections of NDAs and INDs, in the US and abroad. He has also led several R&D groups including most recently the R&D group at AMAG Pharmaceuticals where he was also a Co-inventor of all three AMAG approved drug products, Feraheme, Feridex I. V. and GastroMark. His previous experience includes: 1) 25 years with AMAG pharmaceuticals where he was Vice President of Scientific Operations where he led both the manufacturing and R&D teams. 2) Senior scientist with Petroferm Research Inc., Biotechnology & Specialty Chemicals.  3) Manager at Clinical Assays (Division of Baxter Travenol).

Kent Iverson, B.Sc.

CMC Consultant. 


Kent has over 30 years of manufacturing experience, specializing in the manufacturing of biologic drug products. His expertise includes biopharmaceutical manufacturing and development, including:  due diligence, CMO selection and management, CMC regulatory submission drafting and review, facility design, process development and troubleshooting and technical support of Quality Assurance activities.  His previous experience includes: 1) Vice President, Process Development at Corixa Corporation, 2) Vice President, Manufacturing at Coulter Pharmaceutical, 3) Director of Operational Project Management, Director of Contract Services, Director of Fermentation Manufacturing, Manager of Cell Culture Manufacturing at Immunex, 4) Senior Technical Operator, Fermentation at Genentech, Inc.

Dr. George Shopp, PhD DABT

Toxicology Consultant.


George has 36 years of experience in the fields of toxicology, pharmacology, pharmacokinetics and drug development. This includes two years at toxicology contract research organizations (CROs), 12 years in grant and contract supported basic and applied research (Medical College of Virginia and Lovelace Medical Foundation). Fourteen years in industrial drug development including: 3 years at Synergen responsible for all regulatory and research/investigational toxicology; 2 years at Genentech directing the research toxicology group, and responsible for nonclinical development of growth factors and monoclonal antibodies; and Elan Pharmaceuticals for 9 years responsible for global nonclinical development and research toxicology of small molecule drugs and biopharmaceutics. Dr. Shopp was President of the Board of Directors for the American Board of Toxicology in 2003.

Luana E. Staiger, B.Sc

Regulatory Consultant.


Luana has 35 years of experience in the regulatory field. Including, preparation and submission of documentation to regulatory authorities; liaise with regulatory authorities on behalf of clients; maintain client files and regulatory correspondence. Assist clients in planning and follow-up for key regulatory meetings (e.g., preIND, end-of-phase 2;preNDA).  Her previous experience includes: 1) Vice President, Regulatory Affairs at ChemGenex Pharmaceuticals, 2) Senior Director, Regulatory Affairs at ICON Clinical Research, 3) Vice President, Regulatory Affairs & QA, Director Regulatory Affairs at Matrix Pharmaceutical, Inc., 4) Associate Director, Regulatory Affairs at Gilead Sciences Inc., 5) Group Manager, Regulatory Affairs at Syntex (USA) Inc.

Kris Chavez, B.A.

T1D Project Mangement Consultant. 


Kris brings extensive leadership experience in all stages of biopharmaceutical development involving antibodies, peptides and small molecules. Previously Kris was Vice-President for Project Management at Cambridge Antibody Technology (CAT) Inc. where she was responsible for Program Management.  Kris was Project Director at Genencor developing an HBV vaccine and immunotoxins in oncology.  At  Nektar  (Inhale), Kris  developed antibody treatments for asthma, chronic obstructive pulmonary disease and multiple sclerosis.  She also led the Project Management function at Oread, Inc., a contract research organization. Prior to that she had a successful 20+ year career at Syntex/Roche where she held a number of increasingly responsible CMC positions. She earned her B.A. in Biological Sciences from the University of California, Berkeley.